Inogen (INGN) Részvény Árfolyam
Inogen Árfolyam
Az elmúlt 14 évben a(z) Inogen árbevétele évi 19,0%-kal nőtt, és elérte a 348,67 M USD-t. Az egy részvényre jutó eredmény évi 58,1%-kal nőtt az elmúlt 7 évben. A(z) Inogen esetében a -6,5%-os nettó árrés csökkent a néhány évvel ezelőtti -1,8%-hoz képest. A(z) Inogen 12 hónapos konszenzusos célára 26,00 USD, körülbelül felett az árfolyamot 277,6%-kal. 8 elemzőből 7 vételt javasol — az összesített konszenzus Vétel.
Inogen részvényár
Ezeket az adatokat az Eulerpool API-n keresztül
100 000 kérés/hó ingyen · nincs bankkártya
Inogen üzleti modell és részvényelemzés
Gyakran feltett kérdések a Inogen részvényről
The business model of Inogen Inc is centered around developing and manufacturing innovative medical devices for the oxygen therapy market. Inogen primarily focuses on designing portable oxygen concentrators (POCs) that can enhance the quality of life for individuals requiring oxygen therapy. Inogen's POCs offer flexibility, mobility, and convenience, enabling patients to engage in various activities while receiving the necessary oxygen support. By providing technologically advanced and user-friendly solutions, Inogen aims to improve patient outcomes and enable individuals with respiratory conditions to lead active and independent lives. Inogen Inc is committed to meeting the evolving needs of the oxygen therapy industry by continuously developing and enhancing its product portfolio.
Inogen Inc is primarily active in the medical device industry.
The main competitors of Inogen Inc in the market are Philips Respironics and Invacare Corporation.
Inogen Inc is a renowned medical technology company specializing in the development and manufacture of portable oxygen concentrators. Founded in 2001 and based in Goleta, California, Inogen has revolutionized the industry by providing innovative and efficient oxygen therapy solutions to patients worldwide. With a strong commitment to enhancing the quality of life for those with respiratory conditions, Inogen has built a solid reputation for its cutting-edge products and exceptional customer service. The company's dedication to research, design, and manufacturing excellence has positioned it as a global leader in the oxygen therapy market, ensuring a brighter and healthier future for individuals in need of respiratory support.
Inogen Inc has achieved several significant milestones over the years. One notable achievement is the development of portable oxygen concentrators, revolutionizing the way individuals with respiratory conditions receive oxygen therapy. In 2008, the company received FDA approval for the Inogen One, its first breakthrough product. Inogen Inc has also expanded its operations globally, catering to a wider customer base across different countries. Furthermore, the company has consistently been recognized for its innovation and contributions to the medical industry. These milestones collectively highlight Inogen Inc's commitment to providing high-quality, life-enhancing solutions for individuals with respiratory needs.
Inogen Inc is primarily present in numerous countries and regions worldwide. With its focus on providing innovative and portable oxygen concentrators, Inogen has established a strong presence in various markets. The company's products and services are available across North America, including the United States and Canada, where it has a significant customer base. In addition, Inogen Inc has expanded its operations to international markets, including Europe, Australia, and Asia. Through its global distribution network and partnerships, Inogen continues to reach and serve customers in diverse geographical locations.
Inogen Inc represents values of innovation, quality, and compassion in providing portable oxygen concentrators and respiratory products. With a corporate philosophy focused on improving the quality of life for individuals with respiratory conditions, Inogen strives to enhance mobility, independence, and freedom for patients worldwide. The company's commitment to developing reliable and efficient solutions is evident through its dedication to research and development, customer service, and manufacturing excellence. Inogen Inc exemplifies its core values by providing market-leading products and exceptional support for patients to maintain an active and fulfilling lifestyle.
Az elemzők jelenleg 26,00 USD átlagos célárat adnak a Inogen részvényre (medián: 26,00 USD), ami +277,6 % a legutóbbi árhoz képest. A konszenzus 8 elemzői minősítésen alapul.
8 elemző értékeli jelenleg a Inogen részvényt: 7 vételt, 1 tartást és 0 eladást javasol. 2026-re az elemzők 356,42 M USD árbevételt és -0,75 USD EPS-t várnak a Inogen esetében.
Az aktuális árfolyamon a Inogen részvény 6,14 EUR (6,89 USD).
A Inogen részvény (INGN) 4 tőzsdén jegyzett, többek között: NASDAQ (INGN), SIX (Zürich) (6IO.SW), Frankfurt (6IO.F), Düsseldorf (6IO.DU).
Inogen Inc. is a leading health company specializing in the development, manufacturing, and distribution of respiratory therapy devices. The company's main business is the production of portable oxygen concentrators which can improve the quality of life for patients with health issues. The products offered by Inogen are innovative, space-saving, and lightweight oxygen therapy devices that allow patients to maintain their breathing during daily life activities and have more freedom and independence. These devices are usually smaller and lighter than traditional oxygen systems and designed for easy transportation and operation by patients. Inogen has three main product lines: the Inogen One G5 portable oxygen concentrator, the Inogen at Home electric oxygen concentrator, and the Inogen One G4 portable oxygen concentrator. The Inogen One G5 is a portable oxygen concentrator that offers long battery life and convenient mobility. The Inogen at Home electric oxygen concentrator is a stationary system that provides continuous oxygen supply in the private home environment. The Inogen One G4 is a portable oxygen concentrator that is even smaller and lighter than the Inogen One G5. Inogen also offers accessories for the devices including additional batteries, carrying backpacks, nasal cannulas, and other replacement parts. The company sells its products in the USA and over 30 other countries worldwide. Another business segment of Inogen is the sale of devices to third-party providers including hospitals, doctors, and other healthcare professionals. Inogen provides a comprehensive range of services including service guides, installation, and customer support. Inogen has achieved success due to its technological innovation, high product quality, and customer focus. The company engages in intensive marketing to increase brand awareness and product visibility. Inogen has successful and trained team members in sales, consultation, customer care, and technical support who meet the needs of customers. Inogen follows a co-marketing model that allows them to collaborate with other healthcare partners. These partnerships help the company present its products to a wider customer segment and develop potential business opportunities. As a socially responsible company, Inogen collaborates with various non-profit organizations to achieve its goal of improving the quality of life for patients with respiratory issues. Inogen also strives to act in an environmentally conscious manner and ensures that its devices are environmentally friendly. For example, the devices' batteries are rechargeable and the materials and components are easily reusable. Overall, Inogen's business model focuses on technological innovation, customer orientation, and social responsibility. The company utilizes its core competencies and dedicated employees to create top-notch products and provide high-quality customer service. Inogen is a sound company with robust growth potential and is well-positioned to maintain its market leadership in respiratory therapy.
A várható bevétele Inogen 356,42 M USD. Ez az érték az aktuális pénzügyi adatokon alapul, és a vállalat üzleti teljesítményét tükrözi.
A várható nyeresége Inogen -20,32 M USD. A nettó nyereség a vállalat nyereségességét tükrözi az összes költség levonása után.
A Inogen ár/nyereség mutatója (P/E) jelenleg -9,21. A P/E mutató az aktuális részvényárat az egy részvényre jutó nyereséggel hasonlítja össze, és segít a befektetőknek a Inogen részvény értékelésének megértésében.
A Inogen ár/értékesítés mutatója (P/S) jelenleg 0,52. A P/S mutató a piaci kapitalizációt az éves bevételhez hasonlítja, és a Inogen részvény értékelési mérőszámaként szolgál.
Az Eulerpool minőségi pontszáma a Inogen számára 1/10.
A Inogen ISIN-je US45780L1044. Az ISIN (International Securities Identification Number) a nemzetközi securities azonosító.
A Inogen WKN-je A1XB32. A WKN (Wertpapierkennnummer) egy hatjegyű német értékpapír-azonosító szám.
A Inogen ticker-e INGN. A ticker szimbólum a Inogen részvény tőzsdei kereskedésénél használatos.
Inogen részvény
Inogen Peer Group
Inogen Tőzsdei rövidítés
Inogen FIGI
A Inogen összes alapfundamentuma és mélyreható elemzése
A Inogen részvény Eulerpool-elemzése olyan fontos pénzügyi mutatókat tartalmaz, mint a bevétel, nyereség, P/E arány, P/S arány, EBIT, valamint információk az osztalékról. Vizsgáljuk a részvények, piaci kapitalizáció, adósság, saját tőke és kötelezettségek vonatkozásait is Inogen. Ha részletesebb információt keres ezekről a témákról, részletes elemzéseket kínálunk az aloldalainkon.